Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis[1].
References
[1] AGertz M, et, al. Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design. Journal home page for Blood. Volume 138, Supplement 1, 23 November 2021, Page 2754.
